BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 30877234)

  • 21. Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas.
    Remacha L; Pirman D; Mahoney CE; Coloma J; Calsina B; Currás-Freixes M; Letón R; Torres-Pérez R; Richter S; Pita G; Herráez B; Cianchetta G; Honrado E; Maestre L; Urioste M; Aller J; García-Uriarte Ó; Gálvez MÁ; Luque RM; Lahera M; Moreno-Rengel C; Eisenhofer G; Montero-Conde C; Rodríguez-Antona C; Llorca Ó; Smolen GA; Robledo M; Cascón A
    Am J Hum Genet; 2019 Apr; 104(4):651-664. PubMed ID: 30929736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Germline DLST Variants Promote Epigenetic Modifications in Pheochromocytoma-Paraganglioma.
    Buffet A; Zhang J; Rebel H; Corssmit EPM; Jansen JC; Hensen EF; Bovée JVMG; Morini A; Gimenez-Roqueplo AP; Hes FJ; Devilee P; Favier J; Bayley JP
    J Clin Endocrinol Metab; 2021 Jan; 106(2):459-471. PubMed ID: 33180916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of sequencing platforms and their applications in phaeochromocytoma and paragangliomas.
    Pillai S; Gopalan V; Lam AK
    Crit Rev Oncol Hematol; 2017 Aug; 116():58-67. PubMed ID: 28693800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analytical Performance of NGS-Based Molecular Genetic Tests Used in the Diagnostic Workflow of Pheochromocytoma/Paraganglioma.
    Sarkadi B; Liko I; Nyiro G; Igaz P; Butz H; Patocs A
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Silent genetic alterations identified by targeted next-generation sequencing in pheochromocytoma/paraganglioma: A clinicopathological correlations.
    Pillai S; Gopalan V; Lo CY; Liew V; Smith RA; Lam AK
    Exp Mol Pathol; 2017 Feb; 102(1):41-46. PubMed ID: 27986441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors.
    Babic B; Patel D; Aufforth R; Assadipour Y; Sadowski SM; Quezado M; Nilubol N; Prodanov T; Pacak K; Kebebew E
    Surgery; 2017 Jan; 161(1):220-227. PubMed ID: 27865588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers.
    de Cubas AA; Korpershoek E; Inglada-Pérez L; Letouzé E; Currás-Freixes M; Fernández AF; Comino-Méndez I; Schiavi F; Mancikova V; Eisenhofer G; Mannelli M; Opocher G; Timmers H; Beuschlein F; de Krijger R; Cascon A; Rodríguez-Antona C; Fraga MF; Favier J; Gimenez-Roqueplo AP; Robledo M
    Clin Cancer Res; 2015 Jul; 21(13):3020-30. PubMed ID: 25825477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel SDHB and TMEM127 Mutations in Patients with Pheochromocytoma/Paraganglioma Syndrome.
    Patócs A; Lendvai NK; Butz H; Liko I; Sapi Z; Szucs N; Toth G; Grolmusz VK; Igaz P; Toth M; Rácz K
    Pathol Oncol Res; 2016 Oct; 22(4):673-9. PubMed ID: 26960314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging molecular markers of metastatic pheochromocytomas and paragangliomas.
    Goncalves J; Lussey-Lepoutre C; Favier J; Gimenez-Roqueplo AP; Castro-Vega LJ
    Ann Endocrinol (Paris); 2019 Jun; 80(3):159-162. PubMed ID: 31053249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Somatic EPAS1 Variants in Pheochromocytoma and Paraganglioma in Patients With Sickle Cell Disease.
    White G; Nonaka D; Chung TT; Oakey RJ; Izatt L
    J Clin Endocrinol Metab; 2023 Nov; 108(12):3302-3310. PubMed ID: 37285480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients.
    Calsina B; Currás-Freixes M; Buffet A; Pons T; Contreras L; Letón R; Comino-Méndez I; Remacha L; Calatayud M; Obispo B; Martin A; Cohen R; Richter S; Balmaña J; Korpershoek E; Rapizzi E; Deutschbein T; Vroonen L; Favier J; de Krijger RR; Fassnacht M; Beuschlein F; Timmers HJ; Eisenhofer G; Mannelli M; Pacak K; Satrústegui J; Rodríguez-Antona C; Amar L; Cascón A; Dölker N; Gimenez-Roqueplo AP; Robledo M
    Genet Med; 2018 Dec; 20(12):1652-1662. PubMed ID: 30008476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pheo-Type: A Diagnostic Gene-expression Assay for the Classification of Pheochromocytoma and Paraganglioma.
    Flynn A; Dwight T; Harris J; Benn D; Zhou L; Hogg A; Catchpoole D; James P; Duncan EL; Trainer A; Gill AJ; Clifton-Bligh R; Hicks RJ; Tothill RW
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1034-43. PubMed ID: 26796762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic spectrum in a Canadian cohort of apparently sporadic pheochromocytomas and paragangliomas: New data on multigene panel retesting over time.
    Parisien-La Salle S; Dumas N; Bédard K; Jolin J; Moramarco J; Lacroix A; Lévesque I; Burnichon N; Gimenez-Roqueplo AP; Bourdeau I
    Clin Endocrinol (Oxf); 2022 Jun; 96(6):803-811. PubMed ID: 34750850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic bases of pheochromocytoma and paraganglioma.
    Cascón A; Calsina B; Monteagudo M; Mellid S; Díaz-Talavera A; Currás-Freixes M; Robledo M
    J Mol Endocrinol; 2023 Apr; 70(3):. PubMed ID: 36520714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk assessment of maternally inherited SDHD paraganglioma and phaeochromocytoma.
    Burnichon N; Mazzella JM; Drui D; Amar L; Bertherat J; Coupier I; Delemer B; Guilhem I; Herman P; Kerlan V; Tabarin A; Wion N; Lahlou-Laforet K; Favier J; Gimenez-Roqueplo AP
    J Med Genet; 2017 Feb; 54(2):125-133. PubMed ID: 27856506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Routine genetic screening with a multi-gene panel in patients with pheochromocytomas.
    Sbardella E; Cranston T; Isidori AM; Shine B; Pal A; Jafar-Mohammadi B; Sadler G; Mihai R; Grossman AB
    Endocrine; 2018 Jan; 59(1):175-182. PubMed ID: 28477304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic stratification of inherited and sporadic phaeochromocytoma and paraganglioma: implications for precision medicine.
    Casey R; Neumann HPH; Maher ER
    Hum Mol Genet; 2020 Oct; 29(R2):R128-R137. PubMed ID: 33059362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing Genetic Workup in Pheochromocytoma and Paraganglioma by Integrating Diagnostic and Research Approaches.
    Gieldon L; William D; Hackmann K; Jahn W; Jahn A; Wagner J; Rump A; Bechmann N; Nölting S; Knösel T; Gudziol V; Constantinescu G; Masjkur J; Beuschlein F; Timmers HJ; Canu L; Pacak K; Robledo M; Aust D; Schröck E; Eisenhofer G; Richter S; Klink B
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31212687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic and epigenetic differences of benign and malignant pheochromocytomas and paragangliomas (PPGLs).
    Khatami F; Mohammadamoli M; Tavangar SM
    Endocr Regul; 2018 Jan; 52(1):41-54. PubMed ID: 29453919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutational profile and genotype/phenotype correlation of non-familial pheochromocytoma and paraganglioma.
    Albattal S; Alswailem M; Moria Y; Al-Hindi H; Dasouki M; Abouelhoda M; Alkhail HA; Alsuhaibani E; Alzahrani AS
    Oncotarget; 2019 Oct; 10(57):5919-5931. PubMed ID: 31666924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.